Bisphosphonates may reduce risk of certain breast, colon, and lung cancers
the ONA take:
According to two new studies published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at the Icahn School of Medicine at Mount Sinai in New York, New York, have found that bisposphonates, a commonly used class of drug to treat osteoporosis, may also prevent certain types of breast, colon, and lung cancers.
The first study analyzes how bisphosphonates block abnormal tumor growth through the human epidermal growth factor (HER) receptors, and the second study describes how bisphosphonates could be used in cancer prevention, in combination with existing treatments, and against treatment-resistant cancers. Certain types of breast, colon, and non-small cell lung cancers are driven by genetic mutations that cause the overexpression of HER family receptors.
The study found that bisphosphonates bind to kinase domains for HER proteins, thereby preventing pathway signaling that would ultimately cause cancer growth. This mechanism is similar to that of drugs that inhibit tyrosine kinases like trastuzumab and erlotinib; however, cancers often become resistant to these treatments after the tumor develops a second genetic mutation.
The findings suggest that bisphosphonates may continue to inhibit HER family receptors even after a second mutation is present, making these drugs a potential treatment for those cancers that become resistant to primary therapy.
Bisposphonates may also prevent certain types of breast, colon, and lung cancers.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|